Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer
Rudolph, P ; Kuhling, H ; Alm, Per LU ; Fernö, Mårten LU ; Baldetorp, Bo LU ; Olsson, Håkan LU
and Parwaresch, R
(2003)
In International Journal of Cancer
105(5).
p.674-680
- Abstract
- Searching for new prognostic factors, we investigated the influence of cyclin expression on breast cancer prognosis. A total of 273 archival tumor specimens from patients with pT1/pT2 NO breast cancers treated by surgery and local irradiation were immunostained for cyclins E, A and B. Outcome was evaluated as metastasis-free (MFS) and diseasespecific survival (DSS) over a median observation period of 99 months. In postmenopausal women, DSS was significantly predicted by cyclin E, and in premenopausal patients by cyclin B. No statistical significance was found for cyclin A. When the prognostic impact of cyclins was compared to that of standard prognostic indicators in a multivariate analysis, both cyclin E and cyclin B were selected as... (More)
- Searching for new prognostic factors, we investigated the influence of cyclin expression on breast cancer prognosis. A total of 273 archival tumor specimens from patients with pT1/pT2 NO breast cancers treated by surgery and local irradiation were immunostained for cyclins E, A and B. Outcome was evaluated as metastasis-free (MFS) and diseasespecific survival (DSS) over a median observation period of 99 months. In postmenopausal women, DSS was significantly predicted by cyclin E, and in premenopausal patients by cyclin B. No statistical significance was found for cyclin A. When the prognostic impact of cyclins was compared to that of standard prognostic indicators in a multivariate analysis, both cyclin E and cyclin B were selected as independent predictors of survival in postmenopausal and premenopausal patients, respectively. After inclusion of Ki-67 in the model, cyclin E lost its significance, whereas cyclin B remained the only independent prognostic factor with a hazard ratio of 4.5 (p = 0.026) for tumor-related death. Assessment of cyclin expression may, therefore, refine current prognostic models if considered in relation to menopausal status. The prognostic relevance of cyclins is likely attributable to an influence on proliferation, cell survival and genetic instability. Awareness of the molecular mechanisms leading to deregulated cyclin expression may guide decisions for risk-adapted therapy regimens. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/308901
- author
- Rudolph, P
; Kuhling, H
; Alm, Per
LU
; Fernö, Mårten
LU
; Baldetorp, Bo
LU
; Olsson, Håkan
LU
and Parwaresch, R
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- menopause, prognosis, breast cancer, cell cycle, immunohistochemistry, cyclin E, cyclin B
- in
- International Journal of Cancer
- volume
- 105
- issue
- 5
- pages
- 674 - 680
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:12740917
- wos:000183474000015
- scopus:0037837061
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.11132
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000), Oncology, MV (013035000)
- id
- 67c9e53f-27f4-4b68-85cb-9e7b8c322982 (old id 308901)
- date added to LUP
- 2016-04-01 12:04:38
- date last changed
- 2022-03-28 19:56:13
@article{67c9e53f-27f4-4b68-85cb-9e7b8c322982,
abstract = {{Searching for new prognostic factors, we investigated the influence of cyclin expression on breast cancer prognosis. A total of 273 archival tumor specimens from patients with pT1/pT2 NO breast cancers treated by surgery and local irradiation were immunostained for cyclins E, A and B. Outcome was evaluated as metastasis-free (MFS) and diseasespecific survival (DSS) over a median observation period of 99 months. In postmenopausal women, DSS was significantly predicted by cyclin E, and in premenopausal patients by cyclin B. No statistical significance was found for cyclin A. When the prognostic impact of cyclins was compared to that of standard prognostic indicators in a multivariate analysis, both cyclin E and cyclin B were selected as independent predictors of survival in postmenopausal and premenopausal patients, respectively. After inclusion of Ki-67 in the model, cyclin E lost its significance, whereas cyclin B remained the only independent prognostic factor with a hazard ratio of 4.5 (p = 0.026) for tumor-related death. Assessment of cyclin expression may, therefore, refine current prognostic models if considered in relation to menopausal status. The prognostic relevance of cyclins is likely attributable to an influence on proliferation, cell survival and genetic instability. Awareness of the molecular mechanisms leading to deregulated cyclin expression may guide decisions for risk-adapted therapy regimens.}},
author = {{Rudolph, P and Kuhling, H and Alm, Per and Fernö, Mårten and Baldetorp, Bo and Olsson, Håkan and Parwaresch, R}},
issn = {{0020-7136}},
keywords = {{menopause; prognosis; breast cancer; cell cycle; immunohistochemistry; cyclin E; cyclin B}},
language = {{eng}},
number = {{5}},
pages = {{674--680}},
publisher = {{John Wiley & Sons Inc.}},
series = {{International Journal of Cancer}},
title = {{Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer}},
url = {{http://dx.doi.org/10.1002/ijc.11132}},
doi = {{10.1002/ijc.11132}},
volume = {{105}},
year = {{2003}},
}